AstraZeneca Gilead Merger Intriguing But Unlikely
Bloomberg Rumor Causes A Stir
The possible creation of a pharma giant worth around $230bn of two firms who are leading the industry’s efforts to combat COVID-19 has caught the imagination but the likelihood of a match is limited.
You may also be interested in...
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
AstraZeneca’s half-year results, out on 30 July, will be keenly watched due to the pharma’s attractive near-term growth, pipeline catalysts and its promising COVID-19 vaccine.
The German pharma’s top business development execs explain how they balance IO and targeted cancer therapy in their portfolio, views on major M&A and how to make deals during a global pandemic.